0001437749-23-011514.txt : 20230428 0001437749-23-011514.hdr.sgml : 20230428 20230428090444 ACCESSION NUMBER: 0001437749-23-011514 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20230426 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230428 DATE AS OF CHANGE: 20230428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SAB Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001833214 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 853899721 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39871 FILM NUMBER: 23860718 BUSINESS ADDRESS: STREET 1: 2100 EAST 54TH STREET NORTH CITY: SIOUX FALLS STATE: SD ZIP: 57104 BUSINESS PHONE: 605-679-6980 MAIL ADDRESS: STREET 1: 2100 EAST 54TH STREET NORTH CITY: SIOUX FALLS STATE: SD ZIP: 57104 FORMER COMPANY: FORMER CONFORMED NAME: Big Cypress Acquisition Corp. DATE OF NAME CHANGE: 20201120 8-K 1 sabs20230427_8k.htm FORM 8-K sabs20230427_8k.htm
false 0001833214 0001833214 2023-04-26 2023-04-26 0001833214 sabs:CommonStock00001ParValuePerShareCustomMember 2023-04-26 2023-04-26 0001833214 sabs:WarrantsEachExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150PerShareCustomMember 2023-04-26 2023-04-26
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): April 26, 2023
 
SAB BIOTHERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
 
 
Delaware
001-39871
85-3899721
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
     
2100 East 54th Street North
  
Sioux Falls, South Dakota
  
57104
(Address of Principal Executive Offices)
  
(Zip Code)
 
Registrant’s Telephone Number, Including Area Code: 605 679-6980
 
(Former Name or Former Address, if Changed Since Last Report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange on which registered
Common stock, $0.0001 par value per share
  
SABS
  
The NASDAQ Stock Market LLC
Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
  
SABSW
  
The NASDAQ Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company ☒
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 7.01. Regulation FD Disclosure.
 
On April 26, 2023, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), announced positive top-line results from the Phase 3 National Institutes of Health’s ("NIH") ACTIV-2 clinical trial that assessed SAB-185 in non-hospitalized people with COVID-19 who were at high risk for severe outcomes. Trial data shows that SAB-185 demonstrated benefit in sustained symptom resolution in study participants with COVID-19 caused by the Omicron strain as compared to participants who received a monoclonal antibody combination, REGEN-COV®(casirivimab and imdevimab). 
 
The information furnished under this Item 7.01, including Exhibit 99.1, will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and will not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
 
Cautionary Note Regarding Forward-Looking Statements
 
Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, the development and efficacy of our influenza program, C. diff. program, type 1 diabetes program, and other discovery programs, the results, including timing, of the development of SAB-176, SAB-185, SAB-142 and SAB-195, including SAB-176 Fast Track designation and the outcome of and potential future government and other third-party collaborations or funded programs.
 
These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
 
Item 9.01 Financial Statements and Exhibits.
 
Exhibit Number
Description
99.1
 Press Release of the Company, dated April 26, 2023
104
Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
SAB Biotherapeutics, Inc.
       
Date:
April 28, 2023
By:
/s/ Eddie J. Sullivan
     
Eddie J. Sullivan
Chief Executive Officer
 
 
 EX-99.1 2 ex_508947.htm EXHIBIT 99.1 ex_508947.htm

Exhibit 99.1

 header.jpg

 

SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications

 

SAB-185, a human IgG1 (polyclonal) antibody therapeutic candidate, demonstrated benefit in sustained symptom resolution in patients with Omicron variants of SARS-CoV-2

 

SIOUX FALLS, S.D., April 26, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human, multi-epitope binding immunoglobulin IgG1 (polyclonal) antibodies without the need for human donors, today announced positive top-line results from the Phase 3 National Institutes of Health’s (NIH) ACTIV-2 clinical trial that assessed SAB-185 in non-hospitalized people with COVID-19 who were at high risk for severe outcomes.

 

Trial data show that SAB-185 demonstrated benefit in sustained symptom resolution in study participants with COVID-19 caused by Omicron as compared to participants who received a monoclonal antibody combination, REGEN-COV®(casirivimab and imdevimab). Specifically, 66% of participants treated with SAB-185 reached full symptom resolution for at least 4 consecutive days by Day 28, while only 50% of participants on REGEN-COV® met this endpoint (p=0.010; Figure 1, Table 1), and the median time to symptom resolution for at least 4 consecutive days was 7 days shorter for SAB-185. Also, the median time to symptom resolution for at least 2 consecutive days was 6 days shorter for SAB-185, as compared to those who were treated with REGEN-COV® (p=0.021; Figure 2, Table 1). In the non-Omicron population, the median time to symptom resolution for at least 4 consecutive days was 7 days shorter for SAB-185, and the median time to symptom resolution for at least 2 consecutive days was 4 days shorter for SAB-185 than REGEN-COV®, though neither of these analyses met statistical significance.

 

 

Figure 1: Symptom Resolution Over 4 Consecutive Days

a095499a-435a4029863f28c937c.jpg

 

Figure 2: Symptom Resolution Over 2 Consecutive Days

d44902-38574c928aef1fc6a3a.jpg

 

 

 

Table 1: Symptom Resolution for at least 2 days and 4 days

a698d-34304bd982a2b6ba626.jpg

 

The primary endpoint of the study was the composite of all-cause hospitalizations and deaths. Following the emergence of the Omicron variant in late 2021, the number of these clinical events dropped significantly. An interim review conducted by the study’s Data and Safety Monitoring Board determined that there would not be enough clinical events in this study, with the number of participants specified in the protocol, to arrive at a conclusive result, and the trial was halted. These data were analyzed and showed the primary endpoint was considered inconclusive for both non-inferiority or superiority in non-Omicron and Omicron patients due to the small number of hospitalizations and deaths. Additionally, grade 3 or higher treatment emergent adverse event rates were similar between SAB-185 and REGEN-COV® arms.

 

“The ACTIV-2 data is further validation of the potential of SAB’s platform,” said Eddie J. Sullivan, Ph.D., co-founder, President, and Chief Executive Officer of SAB Biotherapeutics. “It shows that the DiversitAb™ platform can open the door to treatments that are potentially more effective and potent and which remain efficacious over longer periods of time versus monoclonal antibodies. This is not surprising, as SAB-185 has been shown to have pseudovirus neutralizing activity1,2 and protection in animal models ranging from Alpha to Omicron variants3.”

 

Alexandra Kropotova, MD, Chief Medical Officer of SAB Biotherapeutics, said: “In context, these Phase 3 data demonstrate the potential both therapeutic benefits of our fully human multi-epitope binding immunoglobulin antibody therapies as well as their potential to be the modality of choice for COVID-19 and future public health emergencies caused by rapidly mutating viral and bacterial pathogens. This aligns with the FDA’s positive assessment of SAB’s anti-influenza A and B countermeasure. SAB-176 was granted a Fast Track and Breakthrough Therapy designation to treat high risk patients – similar to those at risk for SARS-CoV-2.”

 

1.https://doi.org/10.1101/2021.08.09.454215

 

2.https://doi.org/10.1101/2021.02.06.430072

 

3. https://doi.org/10.1101/2021.07.26.453840

 

Earlier this month, SAB announced that the FDA had granted both Fast Track designation and Breakthrough Therapy designation to SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains. SAB-176 is the first fully-human broadly neutralizing immunoglobulin antibody therapeutic intended to prevent or reduce severe outcomes of Type A and Type B influenza infection in patients at high risk for severe complications, including in patients who are immunocompromised. The Breakthrough Therapy designation was granted to SAB-176 for post-exposure prophylaxis for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains.

 

SAB’s DiversitAb™ platform is a first-of-its-kind technology capable of producing large amounts of fully-human, high-titer, high-avidity multi-epitope binding antibodies across multiple targets without the need for human donors. SAB is leveraging its proprietary platform to discover and develop product candidates with the potential to be first-in-class or best-in-class against complex targets to treat or prevent diseases with significant unmet medical needs. These include infectious respiratory and gastroenterological diseases, immune and autoimmune disorders, and oncology.

 

Direct support for the development of SAB-185 was provided by the US Department of Defense’s (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) on behalf of the Office of the Assistant Secretary of Defense for Health Affairs (OASD-HA), and the Defense Health Agency (DHA) and by the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response, under contract number MCDC 2019-448. The Phase 3 clinical trial was sponsored and funded by the National Institutes of Health (NIH) and further information on the trial can be found here (https://clinicaltrials.gov/ct2/results?cond=&term=NCT04518410&cntry=&state=&city=&dist=).

 

More information on the SAB-185 COVID therapeutic candidate can be found at: https://www.sab.bio/sab-185/

 

More information on the SAB-176 influenza therapeutic candidate can be found at: https://www.sab.bio/sab-176/

 

About SAB Biotherapeutics, Inc.

 

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage biopharmaceutical company focused on the development of powerful and proprietary immunotherapeutic polyclonal human antibodies to treat and prevent infectious diseases and immune and autoimmune disorders. Our development programs include infectious diseases resulting from outbreaks and pandemics, as well as immunological, gastroenterological, and respiratory diseases that have significant mortality and health impacts on immune compromised patients. SAB has applied advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™. Our versatile DiversitAb platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, fully-human polyclonal immunotherapies without the need for human donors. SAB currently has multiple drug development programs underway and collaborations with the US government and global pharmaceutical companies. For more information on SAB, visit: https://www.SAb.bio/ and follow SAB on Twitter and LinkedIn.

 

Forward-Looking Statements

 

Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, the development and efficacy of our influenza program, C. diff. program, type 1 diabetes program, and other discovery programs, the results, including timing, of the development of SAB-176, SAB-185, SAB-142 and SAB-195, including SAB-176 Fast Track designation and the outcome of and potential future government and other third-party collaborations or funded programs.

 

These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

 

CONTACTS:

 

Investor Relations:

 

SABIR@westwicke.com

 

Media Relations:

 

SABPR@westwicke.com

 

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/a095499a-435a-4029-863f-28c937c2590a
https://www.globenewswire.com/NewsRoom/AttachmentNg/37d44902-3857-4c92-8aef-1fc6a3afc13f
https://www.globenewswire.com/NewsRoom/AttachmentNg/195a698d-3430-4bd9-82a2-b6ba626265da

 

 

 
 EX-101.SCH 3 sabs-20230426.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 sabs-20230426_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 sabs-20230426_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Entity, Ex Transition Period Amendment Flag Entity, Central Index Key Class of Stock [Axis] Class of Stock [Domain] CommonStock00001ParValuePerShare Custom [Member] WarrantsEachExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150PerShare Custom [Member] EX-101.PRE 6 sabs-20230426_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 a698d-34304bd982a2b6ba626.jpg begin 644 a698d-34304bd982a2b6ba626.jpg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a095499a-435a4029863f28c937c.jpg begin 644 a095499a-435a4029863f28c937c.jpg M_]C_VP!# ," @," @,# P,$ P,$!0@%!00$!0H'!P8(# H,# L*"PL-#A(0 M#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_VP!# 0,$! 4$!0D%!0D4#0L- M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!3_P 1" #: 4<# 2( A$! Q$!_\0 '0 ! 0 # ,! 0 M 8$!0<" P@!"?_$ $<0 $$ @$" P0'!P(#!0@# $ @,$!1$&$B$'$S$4 M(D%1%196=92ST@@C,C0U87%"D22!H25#56)R%S-24V.2D]25P?#_Q 8 0$! M 0$! 0(#!/_$ #$1 0 " 0,# P(#" ,! ! A$# M$B$3,5$B0:$$<6&Q\",R0H&1T>'Q%#-2P?_: P# 0 "$0,1 #\ _JFB(@UV M:Y!C^.UX)\C9;5BGGCJQNP^).ODL:KS+"WN07<'!D(GY6DSKL5 M^X,8TT]SK78/83W[=0^:SLMBJ^:I&K:#G0F2.337%IZF/:]O?_U-"T%/PSPE M3-Y+*.98M6,A&Z*PRS.Z2-P?UBS7V7L_BH?U+T>'.-J8?$Y&G2KLJU8LG:#(HQIK M?WA]%3RO+6EK7-$K@>@.]"4$_P#6+-?9>S^*A_4GUBS7V7L_BH?U*=RE/G,G M%VLOF.[;^D)3/#QZ3V6>2GMWEMC?(\!KQ[O4>H; (!WW6A\SQ>^DLA'!'5CQ M\)-ESG!K7DM &R6GX@.@?6+-?9>S^*A_4GUBS7V7L_B MH?U+G[+OB_(Y\7L,$1\R5D=B0URTQ^8-2/:';:X,)Z&CJ!Z3UG9 7IL9 MS'P6FQC%LS4;YK%,01N-5LD9(.Y"71%@DWIHDZM#722@Z-]8LU]E[/XJ']2? M6+-?9>S^*A_4J1$$W]8LU]E[/XJ']2?6+-?9>S^*A_4J1$$W]8LU]E[/XJ'] M2?6+-?9>S^*A_4J1$$W]8LU]E[/XJ']2?6+-?9>S^*A_4J1$$W]8LU]E[/XJ M']2?6+-?9>S^*A_4J1$$W]8LU]E[/XJ']2?6+-?9>S^*A_4J1$$W]8LU]E[/ MXJ']2?6+-?9>S^*A_4J1$$W]8LU]E[/XJ']2?6+-?9>S^*A_4J1$$W]8LU]E M[/XJ']2?6+-?9>S^*A_4J1$$W]8LU]E[/XJ']2?6+-?9>S^*A_4J1$$W]8LU M]E[/XJ']2?6+-?9>S^*A_4J1$$W]8LU]E[/XJ']2?6+-?9>S^*A_4J1$$W]8 MLU]E[/XJ']2?6+-?9>S^*A_4J1$$W]8LU]E[/XJ']2?6+-?9>S^*A_4J1$$W M]8LU]E[/XJ']2?6+-?9>S^*A_4J1$&GXOR2'E&-=;BADKNCFDKRPRZZF2,<6 MN&QV/<>H1:'PH_HN7^^+OYI1!;(B("(B"$CPUGD'$>34:-KV&_)D+9JVMG]S M,)"6/[>H#@#KXZ4E0\&^7X_RRSF/FNBEF?%),QSW-ZJI8P]R=$3O?(0.Q&A\ M%T;A?\OEOO2U^851(.2S>'_B))8+H>:BM%J'3"#(1TF/K&RWOOID[_\ U-?! M96&X#SFOFH[E[FDDU6.:*1M.,;8YHDW*'$MV0YG8#MTGYKJ"(.08GPZY_E++ M[>4Y[D,.QN2DL1TJ;(I1) )Y"V-[GL[-='Y8TWN->NUL,KX:<@M7>2/K9F&* M/*QR1MG?)-YH#G=300'=+?+[,;T@$M)WLKIZ(.*V/!#/R8YK(\^T3F@RK)"Z M:QY,CFRSN'?KZ@&B9FB#LF)N^R[!BJLE'%TZTTQL2PPLC?,[U>X- +O^:RD0 M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!$^%']%R_WQ=_- M*)X4?T7+_?%W\TH@MD1*5SD4%W$08OZ(G]G=Y-ILW5)UR M['X- M:P]7H2X@>B"HYUX@5>"QT3/5FN26GN CA+6]+&#J>\EQ [#X#N?@M=1\8,+< MY[G>+.;+!/AZ@MV+3Q]7(1Q2"6-MJ M%L@8\>C@' Z/]UZZ?&\3CLC-D*N,IUKTS!'+:A@:V1[1K37. V1V';^P^2#2 M^'&3J9C$Y&Y1L1VJLN3M%DT9VUP\P^A58IWA7\OEOO2U^851("(B B(@(B(" M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@B?"C^BY?[XN_FE M$\*/Z+E_OB[^:406R^=?V1;=B-O),9.Y\@J>2Z*0RN<',<^8#;#(YL3O=[Q@ M-([$CN%]!WI+$=*P^K$R>TV-QBBD?T->_7N@NT= G7?1TOG;]DS-YS)9CE-3 MD="?%9.C6J1-J36!-J+S+&G=3>SR3U#K<.MP V= :#Z01$03O"_Y?+?>EK\P MJB4[PO\ E\M]Z6OS"J) 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 M1$0$1$!%X>:SS"SK;U@;+=]]'X_]#_LM#R+E$N#S.!I1TS:CR=AU=TC7@>60 MTN!U\M _[*Q&6+WK2-UOU[*%$11L1$01/A1_1%']%R_P!\7?S2 MB"DY)5OW>/Y*OB[ J9&6O(RO.?\ NY"TAKO0^A7*OV?>(MXCP0=M\4NPUW6NX_P"*E[->(/(,2<3(<10IMLU; M$,;W26=MB<2 0 -F1S0/CY;ETI$$IX'U' MP56IWA?\OEOO2U^851("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(M7F MN3XCCOE?2F2JX\S;\L6)0SJUZZWZ^H4[EO%3$M-*M@[=#-Y.Y9;7BJMN!GJ" M2XD!Q 'R6HK,]H<+Z^EI\6M&?G^BV11>4M\ZN8^Q!3Q.)HVI&%L=KZ3=)Y1 M/^KI,&CKY%?L?">0=#>KG>6+]=]5:FM__A5V^98Z\S.*TF?C\\+-1MCQ?XG5 MO7*&[HX6MEY1R*>7_5(;Y;U'YZ: !_@#2W M?&^,U^+U;$->>U9=8G-B6:Y,99'O+6MV7'^S0/\ DKZ8[\LS;ZBTQMB*_?G\ MIASV.'C7BEXDRSL$N2I5\4UKG#SX6-D\TZ'^G9T58XOPSXUA(FVRUDC_,/8=BT#U)8XD]POH#DWG'CF5%<6C8]EE\OV M$M%CJZ#KRR[W0_?IOMO6UPW]DO@F:X6WELN6IWJCVW,)![=A\0^A$1$$[PO^7RWWI:_,*HE.\+_E\M]Z6OS"J) 1$0$1$! M$1 1$0$1$!$1 1$0$1$!$1 1>JU993JS6)-B.)CI':&SH#94I6\1HLA5BGAX M_G9:\S ]CO83IS2-@^OQ"L5F>SE?5IISBTJR.>.9I,T%[WOC/H6#6@P_[JTCQM M2&0/CJPQO'HYL8!'_1>^21L;2Y[@QH]7..@L6]F*.,8'V[<-=I=T#K>!MVB0 MT?WT"=?V69F;/1IZ,4S[S/O/^&8BCY/%KBS:,-J')>UMGH/R<,=:&2226NQW M2Y[6ANSHGT]?[+V1\WNRN9T<7RSHW9$4FR=,8'E%NQ9_BWY7P_\ BW\%=EO> M'IVV\*Q%-8_/<@N5JLLO&S4=)!,^6*6XPNBD:XB-G;UZP >H>F^ZT7$>$\HK MW9 ]S#U=P/CV8X_X6FR//'7L]Q*+CN1Q%^CE'RNG$ED"2 M2!K2"^'7\>G#1 6?@> LQ.;9F;F4N9C*BG[$^S:;$WS&>8Z1I+6,:.IO46@@ M>BI6U8(RPMAC:6=FZ:!T_P"/DKZ:]N5]-9XY>U$1021R1N;;DEGD?,TOE MT)?-T&2C7=C-@ M.SOMW+(4F9*C/5D):R9A87- )&QZC8(V/7N%\_P#[),U% MHY)3B#GW:_DM?;N81RZC8WI)(?L.][8^6D'3_ !2FY7#6Q9XNV8DS MD6/9HXGO]/2?=KQU;)R=KKABE\UK?WA]'=+=_[!5:G M>%_R^6^]+7YA5$@(B("(B B(@(B("(B B(@(B("(I/,SGJ:E=.,V_O^2L4KXF/E;Q.5L4TU=9S$LSF'^C,-5\V29M;*O#I7%NF#]WTGL=GN5D M93P_X5QRO'DJCK?5KX*3NF/5+VTT*:?JK$0JO;(.M MK//CZG%S6MZQLD>H'^/BHK$>)%W,<^S''Z_'+;Z./;$XY7S8O)<'L^2[ M9;KL.WQTMIQG@M/#TZIOU\?D,K#//9]NCI-A_>S$^:]K27=!<#IVCW6]Q>+I M82C#2Q]2"C3A&HZ]:,1QL&]Z#0-#N3_NGIC/N[>F,^Z-NX$\ZR&..?X[:BHS M8^9EFK/<8Z!CS+&6L?&T^^[W.H.!T!L?%4$?!\#%DI[[<57]LFFCLR3%NW&6 M-I;&_OZ%K20"/FMXBFZ>T,[I]A$189$1$!$1 1$0$1$$3X4?T7+_ 'Q=_-*) MX4?T7+_?%W\TH@ME\Z_LP.OV.1NO7LN>_L_\9M<5X_:J M7L?F*ESKV^;*.C#)@7/(,<;)7M80#W T/32#JJ(B"=X7_+Y;[TM?F%42G>%_ MR^6^]+7YA5$@(B("(B B(@(B("(B BTG*N2.XW7I&.C)D+%RRVK%#$YK27$. M.R3V TTJ4YMR3D4W$\FUF$GPW[DEV0=>C:*[007/)'IINUNM9L\^IKUIF(B9 MF/:(F71'N$;'./HT;*DJ?B93R%6*S6Q&S9"[OIA/;JTMWX>YCD#N%\=UQ.&A$_&&0P_2@ M?Y+VM'E1;Z/>#Q_JW[OQVM[,1G_"[/J+3GBL?U_LPL+3AY%)F,CELWF,4?;W M,BK.R;ZOE1'0C!C#AT$]] ]RLVE:P?"\QFY*[<_F[T%1DEJ5C9\@>D.($+". MK]YLD^6/>T=ZTLOCO!8NC.]/(' M_)5&/P>.Q$]V:C1KU)KLOGVI((FL=/)H#K>0/>=H ;/R5M:.RT^GTM/$S&9C MW:-W,+]SD$&.QF!N2PL+'7;=Z.2K'%&]AO$\5SCN9Y/*Y"RRI!-1;5A;0L/<.OW2Z1S7CIZMMTW0[#>]EQUTZ+72M!'_5$F8CNRU#\KFLVN9T,?]/6L)1;CYK4KJKHF M]1:]C07&1CM GY*5^DL#-S;F,>0YG:\0C"V\SDL*;>9>6-_U$Q6VR M6#YEG*,="WD,;3KS6I!;FQYECG%;8,8B<=@2=O>)&M'LJ6GQ?$8_(27JV-K0 M7)(XXGSLC >YC!IC=_)H[#Y+:+,W[8>JE::7[D/7Y$?_ ,MOIT_PCT^2\_3L M.P7ZBY*(B("(B B(@(B("(B B(@(B("(B B(@(B((GPH_HN7^^+OYI1/"C^B MY?[XN_FE$%LB(@(L#,9['8"&*;)78:,4LC86/G>&ASW'0 VE?/8ZUEK&+AO0 M2Y&NQLDU5L@,C&N]"1__ +U'S"#6<+_E\M]Z6OS"J)3O"^U?+?>EK\PJB0$7 MBQ[9&->QP,&";E+-''N.9?6,3)I:,L3XV22;Z(R[J_C/2?=]5/9?Q$.>Y= MAL1#DK_&8)8[AE=&R%[Y9(6MQZ+QX7X/X_(87%WK=. .D=9FLP9C"0^V2^8XF,2N)<0YGQ()ZOBN MOPPQUH8X8F-CBC:&,8T:#0!H +S6>I/LO_'T(_@B?OS^:2\/O#FCX?U+8KN9 M);O.9);DA@;7BD>UO2'-B;[K-@#8'J>ZK.D?)?J+E-IM.9=HB(XB,"(BBB(B M B(@(B("(B B(@(B("(B B(@(B("(B B(@B?"C^BY?[XN_FE$\*/Z+E_OB[^ M:406R_'.#>Y.A_=?JC>6OQ'*KD6"?G&U+->3SWPP/ ?UM;U-!)&AKL[7KV"U M$9EFVZ*S-8S+W\]X#6YS#2;/=FHR5GN DB:QW6QXZ7L(>".X[=0[CX%8>/\ M"FA4Y1ELU/;GN.R4#HIJ[VM8W;FQ,>X%H#N[8(NV]#1UZK!L\3FFF9%8Y&R* M],]Y%B.=XD?V#MMC+ND:^0&M ?W6RXWBGXCE,WM'(),E/8K%PKOF) +2T/<& M>@'4=[WOW]>@"UMCRX5U-6;1$Z?'W>_PWQ=7"XC(TJ<7DUHLG:#&=1=H>8?B M22J2]3@R-26K9;YD,S>ES.HC8^6QW6EX7_+Y;[TM?F%?O+(!*\,,NFG;0XD:[=SI8CN]$S:(],9E+X+P#XIQ_$XZC#](OBHQF.-TF1FV M=C1V [1__I;+CG@OP7BN-=CZ'%\7Y+I73R&Q69-)(]SBYSG.>"7'9^)6LQ." MQ-7$YD1\PCNUK$=8/FDE9(VNT-TUP/5ZO'<$_P"0MKAZ.!AM,L5L[7M.=[4V M#=ALG\1#I!_%[P8-?XW_ '7>UK<^J7")U;[^)QT.Y/ MQ*@*^'Q$]>I4I666R^5K;#8_+!8T.!'5VZ0&DG^^^VUC;^)%M:(QT_ET#J'IONG4/F%SWEF# MQ62S(-GE4>*LM]G A;*V-Y )UO;ALN^';X+'M<>Q#N)8JK+R^%M:.*N^]#Y+#R&$P4V8L3.YG'''.)6^S/F:6-!G:7=+NKL6N]W^VU=D9[L[]?& M>GS]W4NH#U*;TH_*5,$[D%BQ]=O[J[6=VMQ^S^71D4#A^.COTTM<[BV.L9+%3Q\W<86&%\-9L['"8-GQ)RL4H6VYO.A]H:& MB1T#6F,^]V+6@/U\.K>OBLGD&'Q^0AD8_D3*;A1A#Y/-;ML8<[HF&W=NIVP' M?'6DVM;M7GT?/=:=0UO?9-CYJ"APN,J\9QU7ZSQ3,:Z8P6Y)&.$_9P>-!VG] M/^NWJFV$W:O_ (^? MU[\+OJ!]#M.H=NZY_P =P^(KYBU/!RB&X]T%GS:T"YX <>EK2W7]B M3\UYXW&X=^4Q1@Y)%=?":_1$V42.EI MTG4!ZG2YMR#C^&R$SG'E[:7[R1Q:+##HB9Q>WN[T#B6EO_E [:6?RSC>/Y-D M88G?WC=M/Q(:3KX@;] FV/+,WUHB<:?SW76TZAK>^WS M4=RFIB,YB:,$O)&T8X09!8CLL#I6M]QQ)WZ;.B1Z$KR=1QD_"WX7ZP,;&7>Q M-N1RL:]LA.VL'?75Z:'J5-KI-M3,^CC'GW\*_>_3NF]^BE..OQ&'Q^0/U@K7 M(_+%F:D/<0[0!Z22[L"=KUT7#;BKB5CN MH2;8&-(=W;OY?$!9_-,?BLA=E9-R*/#7I(60:$S6O +CKL2-[.O]E=O.&=VK MMF=G/C*V1>,;>F-K=]6AK?S7DN;N(B((GPH_HN7^^+OYI1/"C^BY?[XN_FE$ M%LHC.>%-'.?2$;LC=KT[T_MJVO$?"O$\-S4V3 MI2V'S/B,#62.;TLC)!#>P!)&OXB23\259HM3J7F,3+4ZEIXF4/%5YG@[F1BQ MN,P=VE-;ELQS6LE-#)I[NK3F"NX#6]=G%:SD&'YQR2;&OM8? -CI3^T"!N8E M=',0" UX=4.Q\>VCM=+6KY0<@WCF3.*!.2]G?[.!K?7TG6M]M_+?;>MK$3,< MPQ$X[.*<*\/^2?4]\N.XWC<&,S5J^;#+FYC-"V-ONL(=4(WW(.P?4K88#PCS M7&;U:[C^.8.&W68^.&3Z>L:8QS2WI#/9>GL''7;Y;WI=(\-W9MW#Z9Y")ADN MN4?\4&";RO,=Y7F!A+>OHZ>KI)&]JG6^I?RWU+^7#\#X2Y_C]JO:BP.$L6H9 MFV&S39N;9E#BYSR!4 VYQV?[CMK9W^6O"7D.1S5W*7<)A;=NVZ9SR_-R@ 2, M\OI[4QL-:2!OY]]Z&NXHG4OG.3J7SG+B?*O"WD?-,FRWEL)A9VQB)L4#G@7<>P/LE..Q'"\YJ9SV^=U>8>]36]N M)';MV^2[4B=2W$9.I;$1EQNAX= \EXK5EKT^.8![)(7U_WV;G=J-Q)^UU]%-]I M]TWV\N \5\/^0XWD5PU.+XRK]'6H)6NFS-X+IEG?8'1G9QT/?+YC^G_A>VW:_^UI'< KH7&Z&;CY9R2W> MMV/HB22..A3F+7:TW;Y&D=PTEP:&GO[A/Q"J5>I?.9'FYQW$3HO0U-?PN_Z!?F0\*UK'QO:2?9>YZHVGOV]5VQ$ZE^.>QU+<<]G(*? ^4T\2*#<%@GQBZ;X>[-S= M0ET0#_*:]#\N_P =[*87@/),'@;.(@XWQYU2Q4]B<'9F;W8O>]UH%331[Y[ M:';Y!=?13?;RF^WEQO ^'O*^.YP9.IA\&'>?-9-=V7D\HRR,:QTG:GOJZ6ZW MO9ZG;WU%:IW@GD_I?&91O&L*R[CW1F&0<@LD ,E=*!TFKK^)Q].^BN\HKU+^ M5ZE_+@O+N%\BR7(:[6.+VFKTD.;&&C8/"?&*D-(=&?LL/EQ.+F;(J]R"XGNLSQ%=XGU9,^[B#:]_S7X_ MV*.T8HA7C#W>U]!(/6XM#==>@-]O1=4:26@N&G:[C>]*=2WE-]O+DKN$\J^B M*./BP& ACHRS3UWMS,SG,?(7E_8U""/WCNQ&E@X_POSN,Q^2IP<;P9BR$%:" MP9>067EP@WY9[U>Q[_#Y!=I1-]O)OMY<6P/AIR;!9B?*-PN$M7IH;$$DDN:E M;UB9X?(7!M,!SCTM&SZ!H_NO5C_"WDN-RF-O,PV$D?C7Q.J,?F9/W0CA\EC MX4^KIZ>Y&^Y/R[+MR*]2WE>I;RXKFO#3E6'B&%N4\77L,@JQ9RP^5S97=3V FKW[GM\M!;*AP_ MF'T?Y<^%PEKS,A%E>J?,RA[96%KF-VVH/=;T@:/P&E4^(4W(/I7B\&"@R'3) M?W=M5O*,$, :>KS6O<'.!]!T[(/P0JY2JZG/"[.3EH8XO+BW_ (3L3UG_ M &&DQOAIR/$\E@SD& P?MD,DTD8.3? M;RX8[P?S9EAC>]AI.M;*[8B=2^Y_&T-; M@..!K1H?]LS_ /ZJ\;&6\0:]>67ZO<=?T-+NEN9GV=#>A_PJME%^+-C/P<8B M'&:U^?+26HHV.H&+]RTD]4D@D< Z-H[EH[DZ ]=CFYL3"\B\0LQAJ%\\9P-, MVJ\'O'[_'<'-%E/9A>LW)[O7GU);45*&N2_4?4'=1]&@%I!/_/NKO)<1PN8N>UWL75N6.GH\R>(/]W1& MN_\ D_[K"_\ 9OQ;WO\ L#'^\]LA_<-_B T#Z()@^-F/SV#AN<7C^D)YW^$&SX_G*O)L)1RU$O=2NPM MG@=(PL+F.&VG1[C8(/\ S6P7A#"RO$R*)C8XV-#6L:-!H'8 #Y+S0$1$!$1 M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!ZK,#;5>2%^RR1I:>EQ:= M'^X[A<-=Q_Q3P]."OC+195CH RB21LTK[#K4A>0YQV2(1%TC8'VM(^-W54:'_ /=L M>&%NO@XC?9=\1! >'-'FV/RU^/DUX9&@Z!KH)',8US9!+("W3?AY8B.S\258 MYB&_-13MECD%B$MACD ?LL=U!W2TM[' M0WZZ7*9.*?M 6,U0LR9S'P59,NS)RU:UIOEP5R&AU!Y=%U21MZ">MO2X^8?3 M2^D$6'>(Q&'S]S3B_C?D.569,'F:U/%/RF.L#IML#168P"U%&PQ%P#G;(ZB2 M?F%T+@^&YQC_ Y9C\MEHI>2Q32-CR-P-G=)%YAZ'2A@8WK+/4- [*_15I- M6L?RI[[AKY;'QM=-$ZN'U''HC'_O&N][N3\#\%YFCR?SGD92B(O;A(UOLIV* MNN\>^K^/_P W_142*[EW.2>*?%_$_,X_#-XQR."C:KY.:S;= &PB>KY3Q% > MIK^_66;<->F_[*#N\)\?&\?K15>1B3)^RVF/EEN0M#)W23ECSJ'WFACJX:.W M26NZNK:^ET41P;B_$O&K%<\K6K/(ZM_C,D#_ #JN3D:^2&9L+&L(\N-O4USS M(XC8T0WX=ECP<+\8[7T5#+GYJ)\J!MJV+\4@9()'FR_H\D=;7L\L1M!'ED.) MZMKZ!11'/_"7B_) GRAPHIC 9 d44902-38574c928aef1fc6a3a.jpg begin 644 d44902-38574c928aef1fc6a3a.jpg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header.jpg begin 644 header.jpg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end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information
Apr. 26, 2023
Document Information [Line Items]  
Entity, Registrant Name SAB BIOTHERAPEUTICS, INC.
Document, Type 8-K
Document, Period End Date Apr. 26, 2023
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-39871
Entity, Tax Identification Number 85-3899721
Entity, Address, Address Line One 2100 East 54th Street North
Entity, Address, City or Town Sioux Falls
Entity, Address, State or Province SD
Entity, Address, Postal Zip Code 57104
City Area Code 605
Local Phone Number 679-6980
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company true
Entity, Ex Transition Period false
Amendment Flag false
Entity, Central Index Key 0001833214
CommonStock00001ParValuePerShare Custom [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common stock, $0.0001 par value per share
Trading Symbol SABS
Security Exchange Name NASDAQ
WarrantsEachExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150PerShare Custom [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
Trading Symbol SABSW
Security Exchange Name NASDAQ
XML 12 sabs20230427_8k_htm.xml IDEA: XBRL DOCUMENT 0001833214 2023-04-26 2023-04-26 0001833214 sabs:CommonStock00001ParValuePerShareCustomMember 2023-04-26 2023-04-26 0001833214 sabs:WarrantsEachExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150PerShareCustomMember 2023-04-26 2023-04-26 false 0001833214 8-K 2023-04-26 SAB BIOTHERAPEUTICS, INC. DE 001-39871 85-3899721 2100 East 54th Street North Sioux Falls SD 57104 605 679-6980 false false false false Common stock, $0.0001 par value per share SABS NASDAQ Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share SABSW NASDAQ true false EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 3 23 1 false 2 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.sabs.com/20230426/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports sabs20230427_8k.htm ex_508947.htm sabs-20230426.xsd sabs-20230426_def.xml sabs-20230426_lab.xml sabs-20230426_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sabs20230427_8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 26 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "sabs-20230426_def.xml" ] }, "inline": { "local": [ "sabs20230427_8k.htm" ] }, "labelLink": { "local": [ "sabs-20230426_lab.xml" ] }, "presentationLink": { "local": [ "sabs-20230426_pre.xml" ] }, "schema": { "local": [ "sabs-20230426.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 31, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 2, "memberStandard": 0, "nsprefix": "sabs", "nsuri": "http://www.sabs.com/20230426", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sabs20230427_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.sabs.com/20230426/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sabs20230427_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity, Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "sabs_CommonStock00001ParValuePerShareCustomMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CommonStock00001ParValuePerShare Custom [Member]" } } }, "localname": "CommonStock00001ParValuePerShareCustomMember", "nsuri": "http://www.sabs.com/20230426", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "sabs_WarrantsEachExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150PerShareCustomMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WarrantsEachExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150PerShare Custom [Member]" } } }, "localname": "WarrantsEachExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150PerShareCustomMember", "nsuri": "http://www.sabs.com/20230426", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.sabs.com/20230426/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 19 0001437749-23-011514-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-011514-xbrl.zip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